Aviragen Therapeutics (AVIR) Misses Q3 EPS by 11c
Tweet
Share
E-mailAviragen Therapeutics (NASDAQ: AVIR) reported Q3 EPS of ($0.53), $0.11 worse than the analyst estimate of ($0.42).
For earnings history and earnings-related data on Aviragen Therapeutics (AVIR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- TD Cowen Upgrades Targa Resources (TRGP) to Buy, 'Wet Gas Fuels Growth'
- Jefferies Downgrades Fluence Energy Inc. (FLNC) to Hold
- KeyBanc Reiterates Overweight Rating on Fastly Inc. (FSLY)
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
